ROSSARI Rossari Biotech Q3 FY25 results (Oct–Dec 2024) and concall
Rossari Biotech delivered a resilient performance in Q3 FY25, driven primarily by strong export growth across all segments, despite softer domestic market conditions. While gross margins improved, EBITDA margins were impacted by higher expenses related to ongoing growth initiatives and capacity expansion. The company is making steady progress on new capacity commissioning, though potential delays in Ethylene Oxide supply from Reliance pose a risk to future utilization and profitability.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
| Line item | Q3 FY25 |
|---|---|
| Revenue | 368 |
| EBITDA | 50 |
| Net profit | 31 |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
